By AdjAssocProf Clare Stirzaker

Preprints

So J; Chadwick TB; Fuentes-Guirado M; Vojtech L; Chi LH; Meyer B; Pidsley R; Haynes N; Chalmers H; Tabatabaee A; Ismail A; Cowley KJ; Simpson KJ; Stirzaker C; Parker BS, 2026, Targeting DNA Methylation Reactivates Type I Interferon Signalling in Bone-Metastatic Breast Cancer, http://dx.doi.org/10.64898/2026.06.28.735052

Du Q; Bert S; Armstrong N; Caldon E; Song J; Nair S; Gould C; Luu PL; Khoury A; Qu W; Zotenko E; Stirzaker C; Clark S, 2018, Replication timing shapes the cancer epigenome and the nature of chromosomal rearrangements, http://dx.doi.org/10.1101/251280

Riebler A; Menigatti M; Song JZ; Statham AL; Stirzaker C; Mahmud N; Mein CA; Clark SJ; Robinson MD, 2013, BayMeth: Improved DNA methylation quantification for affinity capture sequencing data using a flexible Bayesian approach, http://dx.doi.org/10.48550/arxiv.1312.3115

Lam D; Clark S; Stirzaker C; Pidsley R, Advances in Prognostic Methylation Biomarkers for Prostate Cancer, http://dx.doi.org/10.20944/preprints202010.0154.v1

Campbell EM; Laven-Law G; Jones A; Challis D; Peters TJ; Smith G; Colino-Sanguino Y; Moulder D; Du Q; Giles KA; Thomson DW; Stirzaker C; Hickey TA; Mora FV; Khoury A; Clark SJ; Achinger-Kawecka J, Androgen stimulation rapidly reorganizes temporal 3D genome and epigenome states to trigger AR-mediated transcription in prostate cancer, http://dx.doi.org/10.1101/2024.12.17.628805

Achinger-Kawecka J; Stirzaker C; Portman N; Campbell E; Chia K-M; Du Q; Laven-Law G; Nair SS; Yong A; Wilkinson A; Clifton S; Milioli HH; Alexandrou S; Caldon CE; Song J; Khoury A; Meyer B; Gee JMW; Schmitt A; Wong ES; Hickey TE; Lim E; Clark SJ, Epigenetic therapy targets the 3D epigenome in endocrine-resistant breast cancer, http://dx.doi.org/10.1101/2021.06.21.449340

Luu P-L; Ong P-T; Loc TTH; Lam D; Pidsley R; Stirzaker C; Clark SJ, MethPanel: a parallel pipeline and interactive analysis tool for multiplex bisulphite PCR sequencing to assess DNA methylation biomarker panels for disease detection, http://dx.doi.org/10.1101/2020.02.09.941013

Murphy KJ; Chambers CR; Reed DA; Channon LM; Mills NE; McKay SE; Lee V; Howell AE; Tran AM; Nobis M; Magenau A; Stoehr J; Pereira BA; Kuepper N; Ritchie S; Gordon K; Trpceski M; Tyma VM; Hafiz S; Johri V; Ang A; Barkauskas DS; Vennin C; Wang XQ; Naeini MM; Meyer B; Parker AL; Gummadi S; Chitti SV; Fajardo DC; Zaratzian A; Tayao M; Da Silva A; Initiative APG; Atlas APM; Cesare AJ; Mathivanan S; Stirzaker C; Latham SL; Croucher DR; Sharbeen G; Phillips PA; Goldstein LD; Lyons RJ; Nagrial A; Pavlakis N; Gill AJ; Biankin AV; Samra J; Caldon CE; Evans TRJ; Chantrill L; Horvath LG; Sansom OJ; Morton JP; Phan TG; Wang Y; Cock T-A; Kinkel SA; Bishop A; Devlin M; Lambert J; Cox TR; Pajic M; Burns CJ; Herrmann D; Timpson P, Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer, http://dx.doi.org/10.64898/2026.07.23.740234

Johnston AD; Antaw F; Lu J; Stirzaker C; Trau M; Korbie D, Unraveling cfDNA Fragmentation Patterns: Linking Chromatin Architecture to Cancer Diagnostic Sensitivity, http://dx.doi.org/10.1101/2024.11.16.623159

Back to profile page